LBA4 Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (mBC): Results from the phase III EVER-002 study

B Xu,F Ma,S Wang,M Yan,W Li,J Sohn,J Tang,X Wang,Y Wang,S-A Im,D Jiang,T Valdez,Y Zhang,K.M Komatsubara,W-P Chung

doi:10.1016/j.annonc.2023.10.186

LBA4 Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (mBC): Results from the phase III EVER-002 study

B Xu, F Ma + Show 13 more

https://doi.org/10.1016/j.annonc.2023.10.186

Copy DOI

Journal: Annals of Oncology

Publication Date: Nov 1, 2023

Affiliation: Sun Yat-sen Memorial Hospital, Jiangsu Province Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, Seoul National University Hospital, First Hospital of Jilin University, Zhejiang Cancer Hospital, Henan Cancer Hospital, Sun Yat-sen University Cancer Center

#Treatment Of Physician’s Choice #Sacituzumab Govitecan + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA4 Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (mBC): Results from the phase III EVER-002 study

Full Text